Cargando…

Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)

Antibody–drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment–drug conjugates (FDCs) could be an alternative. Nevertheless, innovative solutions are needed to implant cysteines as conjug...

Descripción completa

Detalles Bibliográficos
Autores principales: Jolivet, Louis, Ait Mohamed Amar, Imène, Horiot, Catherine, Boursin, Fanny, Colas, Cyril, Letast, Stéphanie, Denevault-Sabourin, Caroline, Allard-Vannier, Emilie, Joubert, Nicolas, Aubrey, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331466/
https://www.ncbi.nlm.nih.gov/pubmed/35893780
http://dx.doi.org/10.3390/pharmaceutics14081524
_version_ 1784758412206145536
author Jolivet, Louis
Ait Mohamed Amar, Imène
Horiot, Catherine
Boursin, Fanny
Colas, Cyril
Letast, Stéphanie
Denevault-Sabourin, Caroline
Allard-Vannier, Emilie
Joubert, Nicolas
Aubrey, Nicolas
author_facet Jolivet, Louis
Ait Mohamed Amar, Imène
Horiot, Catherine
Boursin, Fanny
Colas, Cyril
Letast, Stéphanie
Denevault-Sabourin, Caroline
Allard-Vannier, Emilie
Joubert, Nicolas
Aubrey, Nicolas
author_sort Jolivet, Louis
collection PubMed
description Antibody–drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment–drug conjugates (FDCs) could be an alternative. Nevertheless, innovative solutions are needed to implant cysteines as conjugation sites in the single-chain fragment variable (scFv) format, which is the backbone from which many other antibody formats are built. In addition, the bioconjugation site has the utmost importance to optimize the safety and efficacy of bioconjugates. Our previous intra-tag cysteine (ITC) strategy consisted of introducing a bioconjugation motif at the C-terminal position of the 4D5.2 scFv, but this motif was subjected to proteolysis when the scFv was produced in CHO cells. Considering these data, using three intra-domain cysteine (IDC) strategies, several parameters were studied to assess the impact of different locations of a site-specific bioconjugation motif in the variable domains of an anti-HER2 scFv. In comparison to the ITC strategy, our new IDC strategy allowed us to identify new fragment–drug conjugates (FDCs) devoid of proteolysis and exhibiting enhanced stability profiles, better affinity, and better ability to kill selectively HER2-positive SK-BR-3 cells in vitro at picomolar concentrations. Thus, this work represents an important optimization step in the design of more complex and effective conjugates.
format Online
Article
Text
id pubmed-9331466
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93314662022-07-29 Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs) Jolivet, Louis Ait Mohamed Amar, Imène Horiot, Catherine Boursin, Fanny Colas, Cyril Letast, Stéphanie Denevault-Sabourin, Caroline Allard-Vannier, Emilie Joubert, Nicolas Aubrey, Nicolas Pharmaceutics Article Antibody–drug conjugates (ADCs) derived from a full immunoglobulin-G (IgG) are associated with suboptimal solid-tumor penetration and Fc-mediated toxicities. Antibody fragment–drug conjugates (FDCs) could be an alternative. Nevertheless, innovative solutions are needed to implant cysteines as conjugation sites in the single-chain fragment variable (scFv) format, which is the backbone from which many other antibody formats are built. In addition, the bioconjugation site has the utmost importance to optimize the safety and efficacy of bioconjugates. Our previous intra-tag cysteine (ITC) strategy consisted of introducing a bioconjugation motif at the C-terminal position of the 4D5.2 scFv, but this motif was subjected to proteolysis when the scFv was produced in CHO cells. Considering these data, using three intra-domain cysteine (IDC) strategies, several parameters were studied to assess the impact of different locations of a site-specific bioconjugation motif in the variable domains of an anti-HER2 scFv. In comparison to the ITC strategy, our new IDC strategy allowed us to identify new fragment–drug conjugates (FDCs) devoid of proteolysis and exhibiting enhanced stability profiles, better affinity, and better ability to kill selectively HER2-positive SK-BR-3 cells in vitro at picomolar concentrations. Thus, this work represents an important optimization step in the design of more complex and effective conjugates. MDPI 2022-07-22 /pmc/articles/PMC9331466/ /pubmed/35893780 http://dx.doi.org/10.3390/pharmaceutics14081524 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jolivet, Louis
Ait Mohamed Amar, Imène
Horiot, Catherine
Boursin, Fanny
Colas, Cyril
Letast, Stéphanie
Denevault-Sabourin, Caroline
Allard-Vannier, Emilie
Joubert, Nicolas
Aubrey, Nicolas
Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
title Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
title_full Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
title_fullStr Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
title_full_unstemmed Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
title_short Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment–Drug Conjugates (FDCs)
title_sort intra-domain cysteines (idc), a new strategy for the development of original antibody fragment–drug conjugates (fdcs)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331466/
https://www.ncbi.nlm.nih.gov/pubmed/35893780
http://dx.doi.org/10.3390/pharmaceutics14081524
work_keys_str_mv AT jolivetlouis intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT aitmohamedamarimene intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT horiotcatherine intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT boursinfanny intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT colascyril intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT letaststephanie intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT denevaultsabourincaroline intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT allardvannieremilie intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT joubertnicolas intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs
AT aubreynicolas intradomaincysteinesidcanewstrategyforthedevelopmentoforiginalantibodyfragmentdrugconjugatesfdcs